|
|
Volumn 21, Issue 6, 2015, Pages 786-790
|
|
Relapses in patients treated with fingolimod after previous exposure to natalizumab
a
e
PSI
(Switzerland)
|
|
Author keywords
ARR; Fingolimod; FIRST; multiple sclerosis; natalizumab; relapse control
|
|
Indexed keywords
BETA INTERFERON;
BETA1A INTERFERON;
CORTICOSTEROID;
FINGOLIMOD;
GLATIRAMER;
NATALIZUMAB;
IMMUNOLOGIC FACTOR;
ADULT;
AGED;
ARTICLE;
CONTROLLED STUDY;
DISEASE ACTIVITY;
DISEASE DURATION;
DRUG EFFICACY;
DRUG EXPOSURE;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
EXPANDED DISABILITY STATUS SCALE;
FEMALE;
HUMAN;
MAJOR CLINICAL STUDY;
MALE;
MULTIPLE SCLEROSIS;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OBSERVATIONAL STUDY;
OPEN STUDY;
PHASE 3 CLINICAL TRIAL;
POST HOC ANALYSIS;
RELAPSE;
TREATMENT DURATION;
MIDDLE AGED;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
PHASE 3 CLINICAL TRIAL (TOPIC);
TIME;
TREATMENT OUTCOME;
ADULT;
CLINICAL TRIALS, PHASE III AS TOPIC;
FEMALE;
FINGOLIMOD HYDROCHLORIDE;
HUMANS;
IMMUNOLOGIC FACTORS;
MALE;
MIDDLE AGED;
MULTIPLE SCLEROSIS, RELAPSING-REMITTING;
NATALIZUMAB;
TIME FACTORS;
TREATMENT OUTCOME;
|
|
EID: 84930516810
PISSN: 13524585
EISSN: 14770970
Source Type: Journal
DOI: 10.1177/1352458514549404 Document Type: Article |
|
Times cited : (24)
|
|
References (12)
|
